Praxis Precision Medicines, Inc.
relutrigine
SCN2A/SCN8A-DEE and Broad DEEs
Countdown
83days
FDA decision · Sep 27, 2026
What's at stake
The FDA's approval decision on relutrigine for SCN2A/SCN8A-DEE and Broad DEEs is due Sep 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 12h ago
“Assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027.”